510(k) · Cleared
ClearedBD Phoenix Automated Microbiology System - Cefepime (GN) , Ceftriaxone (GN), Cefotaxime (GN), 0.5-64 UG/ML
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Becton, Dickinson & CO · LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
Cleared on Apr 12, 2006 as substantially equivalent to K020321 (Becton, Dickinson & CO, 2002) and 2 other predicates after a 50-day review. Its family tree reaches back 2 generations to 2002. 2 later devices descend from it.
- Decided
- Apr 12, 2006
- Review
- 50 days
- Class
- Class II
- Product code
- LON
- Recalls
- None
- Predicates
- 4
Its longest line of descent runs back 2 generations to K020322 (2002). 5 ancestors in all. 2 later devices descend from it, 2 citing it directly.
- Root · 2 generations backK020322 BD Phoenix Automated Microbiology SystemBecton, Dickinson & CO · 2002
- 1 generation backK032655 BD Phoenix Automated Microbiology System-Ceftriaxone 0.5-64 UG/MLBecton, Dickinson & CO · 2003
- This deviceK060444 BD Phoenix Automated Microbiology System - Cefepime (GN)…Becton, Dickinson & CO · 2006
- Descendant · cites it directly · 0 of its ownK063301 BD Phoenix Automated Microbiology System - Cefepime (GN) 0.5-64UG/MLBecton, Dickinson & CO · 2006
- Descendant · cites it directly · 0 of its ownK062944 BD Phoenix Automated Microbiology System - Ceftriaxone (GN)…Becton, Dickinson & CO · 2006
Most influential descendants
Showing 2 of 2 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K020322 | BD Phoenix Automated Microbiology System | Becton, Dickinson & CO | 2002 | — |
| −1 | K032655 | BD Phoenix Automated Microbiology System-Ceftriaxone 0.5-64 UG/ML | Becton, Dickinson & CO | 2003 | — |
| 0 (this device) | K060444 | BD Phoenix Automated Microbiology System - Cefepime (GN) , Ceftriaxone (GN)… | Becton, Dickinson & CO | 2006 | — |
| +1 | K063301 | BD Phoenix Automated Microbiology System - Cefepime (GN) 0.5-64UG/ML | Becton, Dickinson & CO | 2006 | — |
| +1 | K062944 | BD Phoenix Automated Microbiology System - Ceftriaxone (GN) 0.5-64UG/ML | Becton, Dickinson & CO | 2006 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2002 | 2 | 0 |
| 2004 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2006 | 2 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LON? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LON device
- #1 K260619 VITEK 2 AST-Streptococcus Cefepime (<=0.06 –…score 13.3 · 5 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (4)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary; numbers the summary cites that cannot be its predicate are marked – and kept off the family tree.
| Type | Number | Device | Decided |
|---|---|---|---|
| Kept off the family tree | N005010 | VITEK System Number could not be read | |
| * | K020321 | BD Phoenix Automated Microbiology SystemSummary page 1…ES: VITEK® System (PMA No. N505 10) and BD Phoenix TM Automated Microbiology System with Gatifloxacin (K02032 1, May 23, 2002), Cefepime-0.5-64 Iig/mL (K032675, March 1,… | 2002 |
| * | K032675 | BD Phoenix Automated Microbiology System-Cefepime (GN) 0.5-65 UG/MLSummary page 1…Automated Microbiology System with Gatifloxacin (K02032 1, May 23, 2002), Cefepime-0.5-64 Iig/mL (K032675, March 1, 2004) and Ceftriaxone -0.5-64 gtg/mL (K032655,… | 2004 |
| * | K032655 | BD Phoenix Automated Microbiology System-Ceftriaxone 0.5-64 UG/MLSummary page 1…May 23, 2002), Cefepime-0.5-64 Iig/mL (K032675, March 1, 2004) and Ceftriaxone -0.5-64 gtg/mL (K032655, October 6, 2003) INTENDED USE: The BD Phoenix Tm Automa… | 2003 |
What descends from it? (2)
2 later devices cite it directly; ranked here by how many devices descend from each in turn.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 4 years and passes through 1 company; a new generation was cleared every 2.5 years on median.
- 1 of the 5 ancestors has a recall of any class.
- Of its descendants, K063301 (Becton, Dickinson & CO, 2006) has gone furthest, with 0 descendants of its own.
- 102 other devices also cite its predicate K020321.
How does its category compare?
All LON devicesLON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · LON
5in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · LON
90in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · LON
1in 2025
Class I (2 since 2007) Class II/III not classified
Adverse event reports per year · LON
690in 2025
MAUDE reports naming product code LON, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 19 | 50 | 0 | 3 |
| 2008 | 7 | 66 | 1 | 1 |
| 2009 | 8 | 76 | 0 | 0 |
| 2010 | 1 | — | 116 | 3 |
| 2011 | 8 | 85 | 3 | 4 |
| 2012 | 10 | 200 | 3 | 9 |
| 2013 | 7 | 115 | 0 | 3 |
| 2014 | 4 | 90 | 2 (2) | 10 |
| 2015 | 0 | — | 0 | 41 |
| 2016 | 3 | 242 | 2 | 94 |
| 2017 | 10 | 89 | 1 | 197 |
| 2018 | 4 | 88 | 6 | 512 |
| 2019 | 8 | 84 | 1 | 315 |
| 2020 | 5 | 81 | 8 | 218 |
| 2021 | 5 | 268 | 0 | 232 |
| 2022 | 8 | 189 | 15 | 180 |
| 2023 | 11 | 210 | 0 | 453 |
| 2024 | 2 | — | 1 | 418 |
| 2025 | 5 | 90 | 1 | 690 |
| 2026 | 4 | 146 | 6 | — |
What is it indicated for?
The BD PhoenixTM Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus, and Streptococcus. This…
Read the full statement (227 words)
The BD PhoenixTM Automated Microbiology System is intended for in vitro quantitative
determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most
Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for
Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure
culture belonging to the genera Staphylococcus, Enterococcus, and Streptococcus.
This premarket notification is for additional organism groups and BD Phoenix Tm Automated
Microbiology System with cefepime (0.5-64 gg/mL) and ceftriaxone (0.5-64 p.g/mL) on Gram-
negative ID/AST or AST only Phoenix panels.
Cefepime has been shown to be active in vitro against most strains of microorganisms listed below,
as described in the FDA-approved package insert for this antimicrobial agent.
Active In Vitro and in Clinical Infections Against:
Enterobacter species Pseudomonas aeruginosa
Escherichia coli
Klebsiella pneumoniae
Active In Vitro Against:
Acinetobacter iwoffi Pantoea agglomerans
Citrobacter koseri Providencia rettgeri
Citrobacter freundii Providencia stuartii
Hafnia alvei Serratia marcescens
Klebsiella oxytoca
Morganella morganii
Ceftriaxone has been shown to be active in vitro against most strains of microorganisms listed
below, as described in the FDA-approved package insert for this antimicrobial agent.
Active In Vitro and in Clinical Infections Against:
Acinetobacter calcoaceticus Klebsiella oxytoca Serratia marcescens
Enterobacter aerogenes Klebsiella pneumoniae Pseudomonas aeruginosa
Enterobacter cloacae Morganella morganii
Escherichia coli Proteus mirabilis
Active In Vitro Against:
Citrobacter koseri (formerly C. diversus)
Citrobacter freundii
Providencia species (including Providencia rettgeri)
Salmonella species
Shigella species
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K060444 · printed Nov 5, 2026
Cite this page
510(k) Report. “K060444: BD Phoenix Automated Microbiology System - Cefepime (GN) , Ceftriaxone (GN), Cefotaxime (GN), 0.5-64 UG/ML.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K060444
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026